Chattem FY 1996 second quarter sales advance 12.2% to $30.4 mil..
This article was originally published in The Rose Sheet
CHATTEM SALES RISE 12.2% TO $30.4 MIL. FOR SECOND QUARTER FY 1996 (ended May 31), the company announced June 20. U.S. sales were ahead 4%, spurred by the additions of the Gold Bond medicated powder and cream brands and the May 1 launch of pHisoDerm antibacterial skin cleanser ("The Rose Sheet" Feb. 5, p. 7), the company said
You may also be interested in...
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
AzarGen and iBio have advanced their alliance, with the latter revealing it would now begin manufacturing and characterizing additional supplies of plant-based rituximab, to enable pre-clinical studies comparing it with Roche’s MabThera original.